A Houston-area company has created an easy-to-use health-check app for employees returning to work. Pexels

A Woodlands-based health services company recently announced a new app that can serve as a self-service pre-screening tool for COVID-19 to be used by employees to return to their workplace.

Axiom Medical created the CheckIn2Work app to make the transition into the workplace after the coronavirus crisis safer and easier, making it simple for businesses and offices to reopen after stay-at-home orders shut down workplaces during the height of the pandemic.

"Given the current challenges we have all experienced with COVID-19, we recognize the workplace will be forever changed," says Axiom Medical President and CEO Mark Robinson. "Our CheckIn2Work app simply adds another layer to protecting the health of team members, customers, and vendors from the risk of infectious disease in the workplace."

The app includes features such as a 24/7 self-service illness screening with the latest screening criteria approved by Chief Medical Officer Scott Cherry. The app also includes immediate access to U.S.-based Clearance Center for exposure/illness alerts, real-time reporting, and ongoing best practices to reduce the spread of the virus in the work environment.

When an app user is flagged as exposed to the virus, Axiom Medical's Rapid Response Contagious Respiratory Illness Assessment Clearance Center professionals can conduct secondary screening procedures via a phone call to confirm cases and eliminate false positives.

The app has 50,000 users already from Axiom's new and existing clients who have signed on to the platform. Some of their partners include BJ Services, Tyson Foods, ISS Facility Services, and Fort Bend Kia, Robinson says it creates safe and healthy facilities for both employees and customers.

"It enables our clients to be appropriately responsive to trying to screen out the infection in their workplace," says Robinson, "It also gives employees confidence that returning to work and exposing themselves to their coworkers is safe while providing customers who have contact with the employees with the confidence who they will be interacting with has been screened and cleared."

For the health services company, keeping employees safe has been the heart of their mission since it was founded more than two decades ago. Axiom Medical markets itself as an employer's outsourced "in house" medical department, managing a complete array of occupational health services such as scheduling exams, verifying results for accuracy, and maintaining records.

"Our focus is on the health of the worker in the workplace," says Robinson. "Both our traditional services and our new service all focus on keeping people as healthy as possible, returning them to work as quickly as possible after an injury or illness keeps them out of the workplace, and making sure they are tested for a variety of risks."

CheckIn2Work is now available on iOS and Android mobile devices including a web portal where employees can check in before work every day to check for symptoms of COVID-19. The app is adaptable with language settings in English and Spanish and allows for customizable questions to fit an organization's needs.

"I hope we can continue to take this seriously and take good precautions," says Robinson. "This is a really horrible disease, it isn't just about the people who die as a result, it's also about those who are permanently disabled because of it. Those weeks in a hospital are mirrored by more weeks in recovery before they can even think about working again."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.